Pennsylvania Hospital surgeon receives grant to develop molecular cardi...(ise for eventually prolonging and enhanc...)
Navigation Links
Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
Date:11/28/2007
ise for eventually prolonging and enhancing the quality of life for many patients with heart disesase."
Dr. Bridges new study under the National Heart, Lung and Blood Institute grant will focus on one of the most promising transgene candidates with potential for healing the heart. Specifically, up to 100 trillion genes will be delivered to each heart, which is expected to arrest the progression of heart failure and possibly lead to recovery of heart function within several weeks.
'/>"/>
| Contact: Lee-Ann Landis landisl@uphs.upenn.edu 215-829-8043 University of Pennsylvania School of Medicine Source:Eurekalert |
Related biology news :
1. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
2. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
3. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
4. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
5. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
6. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
7. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
8. Cardiologists and heart surgeons meet for Controversies and Advances conference
9. Rutgers Genetics receives $7.8 million for autism research
10. Herr receives Heinz Award for Technology, the Economy and Employment
11. UCI receives $5M from Edwards Lifesciences
Post Your Comments:
Breaking Biology News(10 mins):Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Technology guide 3A Principles applications trends 8858 1Technology guide 3A Principles applications trends 8858 2Reportable Food Registry Draft Guidance Published for Comment by FDA 49058 1Reportable Food Registry Draft Guidance Published for Comment by FDA 49058 2Video 3A BeautyScoop 28R 29 Is a Trip to Your Nutritionist and Dermatologist in One Single Packet Lauren Slayton NYC Nutritionist 26 Owner of FoodT 49053 1Video 3A BeautyScoop 28R 29 Is a Trip to Your Nutritionist and Dermatologist in One Single Packet Lauren Slayton NYC Nutritionist 26 Owner of FoodT 49053 2
Other Biology News:Malaria vaccine prompts victims' immune system to eliminate parasite from mosquitoes 2Malaria vaccine prompts victims' immune system to eliminate parasite from mosquitoes 3Temperament linked to onset of cancer and early death in female rats 2Coral reefs are increasingly vulnerable to angry oceans 2Coral reefs are increasingly vulnerable to angry oceans 3
Breaking Biology Technology:Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 2Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 3Cell Biosciences Acquires Protein Forest 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4
[0] Vivakor Announces Additions to Board of Directors and Scientific Advisory Board[0] Cell Biosciences Acquires Protein Forest[0] ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
Other Biology Technology:CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 3CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 4CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 5Vermillion Announces Appointment of John Hamilton to Board of Directors 2Amnis Announces Release of Powerful New Image Data Analysis Software 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |